MedPath
NMPA Approval

Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation

H20190055

April 7, 2020

H20190055

Drug Information

氟替美维吸入粉雾剂

全再乐

吸入粉雾剂

每泡含糠酸氟替卡松100µg、乌美溴铵62.5µg(按C₂₉H₃₄NO₂计)与三苯乙酸维兰特罗25µg(按C₂₄H₃₃Cl₂NO₅计),递送剂量为糠酸氟替卡松92µg、乌美溴铵55µg(按C₂₉H₃₄NO₂计)与三苯乙酸维兰特罗22µg(按C₂₄H₃₃Cl₂NO₅计)。

化学药品

April 7, 2020

November 3, 2024

Company Information

Applicant Company

12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Manufacturing Company

glaxo operations uk ltd (trading as glaxo wellcome operations)

Priory Street,Ware, SG12 0DJ Hertfordshire, United Kingdom.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

氟替美维吸入粉雾剂 - NMPA 批准文号 | MedPath